Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product News - AKN

- Securities Registration (section 12(b)) (8-A12B)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF...

-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING...

Safety First Trust Series 2006-5 - Prospectus filed pursuant to Rule 424(b)(2) (424B2)

Filed pursuant to Rule 424(b)(2) Registration Nos. 333-135867, 333-135867-06 and 333-135867-11 CALCULATION OF REGISTRATION FEE ...

Safety First Trust Series 2006-5 - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)

Filed Pursuant to Rule 433 Registration Nos. 333-135867, 333-135867-06 and 333-135867-11 Equity First Protection First ...

American Stock Exchange Lists Safety First Trust Series 2007-4 Principal-Protected Trust Certificates Linked to a Global Index B

NEW YORK, Nov. 23 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) opened trading today on Safety First Trust Series 2007-4...

Akorn, Inc. Signs an Exclusive Supply Agreement For Hydase(TM) (Hyaluronidase Injection, USP) 150 Units/mL, an NDA Product

Akorn, Inc. (AMEX: AKN) today announced that it has signed an Exclusive Supply Agreement with PrimaPharm, Inc., a privately-held...

Akorn, Inc. Announces Move to Nasdaq Global Market

Akorn, Inc. (AMEX:AKN) today announced that its common stock listing application for the Nasdaq Global Market (Nasdaq) has been...

Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)

Akorn, Inc. (AMEX: AKN) today announced the positive results of a Phase III pivotal trial for Akten?. The clinical trial was a...

Akorn, Inc. Signs Exclusive Definitive Agreement For the Development and Supply of Three Ophthalmic ANDA Drug Products

Akorn, Inc. (AMEX: AKN) today announced that it has signed a Definitive Agreement with Azad Pharma, a privately-held...

Akorn, Inc. and Strides Arcolab Limited Agree to Expand the Akorn-Strides, LLC Joint Venture Product Pipeline to Twenty-Nine AND

Akorn, Inc. (AMEX: AKN) and Strides Arcolab Limited (NSE: STAR, BSE: 532531) today announced that both Companies have agreed to...

Akorn, Inc. and Serum Institute of India, Ltd. Announce the Signing of a Definitive Development and Exclusive Distribution Agree

Akorn, Inc. (AMEX:AKN) and Serum Institute of India, Ltd. today announced that they have entered into a Definitive Development...

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AKN)

Get an advanced news scanner tailored to your needs by ADVFN

AKN News

- Securities Registration (section 12(b)) (8-A12B)

-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)

Safety First Trust Series 2006-5 - Prospectus filed pursuant to Rule 424(b)(2) (424B2)

Safety First Trust Series 2006-5 - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)

American Stock Exchange Lists Safety First Trust Series 2007-4 Principal-Protected Trust Certificates Linked to a Global Index B

Akorn, Inc. Signs an Exclusive Supply Agreement For Hydase(TM) (Hyaluronidase Injection, USP) 150 Units/mL, an NDA Product

Akorn, Inc. Announces Move to Nasdaq Global Market

Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)

Akorn, Inc. Signs Exclusive Definitive Agreement For the Development and Supply of Three Ophthalmic ANDA Drug Products

Akorn, Inc. and Strides Arcolab Limited Agree to Expand the Akorn-Strides, LLC Joint Venture Product Pipeline to Twenty-Nine AND

Akorn, Inc. and Serum Institute of India, Ltd. Announce the Signing of a Definitive Development and Exclusive Distribution Agree

Akorn, Inc. and Natco Pharma Limited Add Two Injectable Drug Products To API Supply and Margin Sharing Agreement

Akorn, Inc. Reports Third Quarter 2006 Revenues of $14.5 million and 41% Gross Margin

Akorn, Inc. Announces Third Quarter 2006 Earnings Release and Conference Call Information

Akorn Announces $3.5 Million Purchase Order For Calcium-DTPA and Zinc-DTPA

AKN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AKN) News

Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AKN)

Get an advanced news scanner tailored to your needs by ADVFN

AKN News

- Securities Registration (section 12(b)) (8-A12B)

-National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25)

Safety First Trust Series 2006-5 - Prospectus filed pursuant to Rule 424(b)(2) (424B2)

Safety First Trust Series 2006-5 - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)

American Stock Exchange Lists Safety First Trust Series 2007-4 Principal-Protected Trust Certificates Linked to a Global Index B

Akorn, Inc. Signs an Exclusive Supply Agreement For Hydase(TM) (Hyaluronidase Injection, USP) 150 Units/mL, an NDA Product

Akorn, Inc. Announces Move to Nasdaq Global Market

Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)

Akorn, Inc. Signs Exclusive Definitive Agreement For the Development and Supply of Three Ophthalmic ANDA Drug Products

Akorn, Inc. and Strides Arcolab Limited Agree to Expand the Akorn-Strides, LLC Joint Venture Product Pipeline to Twenty-Nine AND

Akorn, Inc. and Serum Institute of India, Ltd. Announce the Signing of a Definitive Development and Exclusive Distribution Agree

Akorn, Inc. and Natco Pharma Limited Add Two Injectable Drug Products To API Supply and Margin Sharing Agreement

Akorn, Inc. Reports Third Quarter 2006 Revenues of $14.5 million and 41% Gross Margin

Akorn, Inc. Announces Third Quarter 2006 Earnings Release and Conference Call Information

Akorn Announces $3.5 Million Purchase Order For Calcium-DTPA and Zinc-DTPA

AKN Discussion

Your Recent History

Company

Business

Popular

Get The App